Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC

About this update from Helix Biopharma Corp.

[{"type":"text","content":"\n\n\n\nAURORA, Ontario, March 12 /CNW/ -- Helix BioPharma Corp. (TSX, FSE:\n"HBP") announced that its registration statement on Form 20-F has been\ndeclared effective by the U.S. Securities and Exchange Commission ("SEC").\n\n\n\n\n\nAccordingly, Helix's common shares are now registered with the SEC\npursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.\nRegistration of Helix's shares in the United States allows its shares to be\nsolicited and traded by licensed brokers in the United States in compliance\nwith SEC regulations and blue sky requirements in various states in the United\nStates.\n\n\n\n\n\n"We are excited for this registration which we believe provides us with a\nnecessary foundation as we plan to move toward larger capital markets," said\nJohn Docherty, president of Helix BioPharma. "We are continuing to evaluate\nour options for our next step as we look to broaden our U.S. investor base and\ntrading liquidity."\n\n\n\n\n\nThe Company's registration statement on Form 20-F is a full registration\nof the Company's common shares with the SEC as a foreign private issuer\nsimilar to a Form 10 filing for a domestic issuer in the United States.\nHelix's registration statement, as amended, has been filed with the SEC and\nCanadian Securities Administrators and is available online at\nwww.sec.gov/edgar.shtml and www.sedar.com, respectively.\n\n\n\n\n\nAs a result of the registration statement being declared effective, Helix\nwill be obligated to file continuous disclosure documentation applicable to\nforeign private issuers with the SEC and will be obligated to prepare a\nreconciliation of its annual financial statements to generally accepted\naccounting principles in the United States.\n\n\n\nAbout Helix BioPharma Corp.\n\n\n\nHelix BioPharma Corp. is a biopharmaceutical company specializing in the\nfield of cancer therapy. The Company is actively developing innovative\nproducts for the prevention and treatment of cancer based on its proprietary\ntechnologies. Helix's product development initiatives include its Topical\nInterferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed\non the TSX under the symbol "HBP".\n\n\n\nFor further information contact:\n\n\n\nInvestor & Media Relations\nIan Stone Robert Flamm, Ph.D.\nRusso Par...

More updates from Helix Biopharma Corp.